Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

SanegeneBio, Genentech sign $1.5bn global RNAi licensing deal

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi programmes utilising SanegeneBio’s technology platform.

Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs through a global licensing agreement that could generate up to $1.5 billion for the Chinese biotech. Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program. SanegeneBio agreed to oversee early development activities while Gen…

Biotech firm Genentech announces $2 billion investment in Holly Springs facility

Leading biotechnology company Genentech recently announced that it is doubling its investment in a new Holly Springs manufacturing facility—bringing its investment to approximately $2 billion.  The investment is to create a state-of-the-art manufacturing facility, set to be operational by 2029, that will create treatments for metabolic conditions like obesity. The facility, which broke ground in August 2025, is expected to support more than 2,00…

SanegeneBio licenses RNAi candidate to Genentech for $200M upfront

Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B. The Roche unit will pay $200 million upfront for the global ...